Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

Cancer

Volumn 109, Issue 5, 2007, Pages 939-948

  Hotta, Katsuyuki ^a   Fujiwara, Yoshiro ^a   Matsuo, Keitaro ^b   Suzuki, Takeshi ^b   Kiura, Katsuyuki ^a   Tabata, Masahiro ^a   Takigawa, Nagio ^a   Ueoka, Hiroshi ^c   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL SANYO HOSPITAL   (Japan)

Author keywords

Carboplatin; Cisplatin; Nonsmall cell lung cancer; Survival improvement

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PLATINUM DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE REGRESSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; DRUG THERAPY; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 33847358791     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22478     Document Type: Article

References (26)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899-909.
2. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002;20:23s-33s.
3. Baggstrom MQ, Socinski MA, Hensing TA, Poole C. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol. 2002;21:306a. Abstract 1222.
4. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409-422.
5. Kelly K, Crowley I, Bunn PA Ir, et al. Randomized Phase HI trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-3218.
6. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, Phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX326 Study Group. J Clin Oncol. 2003;21:3016-3024.
7. Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y. Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol. 2006;11:167-175.
8. Sandler AB, Gray R, Brahmer J, et al. Randomized Phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. Proc Am Soc Clin Oncol. 2005;23. Abstract 4.
9. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of Phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001;19:1734-1742.
10. Wakelee HA, Bernardo P Johnson DH, Schiller JH. Changes in the natural history of nonsmall cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer. 2006;106:2208-2217.
11. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Staging Manual. 6th ed, Philadelphia, Pa: Springer; 2002.
12. Sobin LH, Wittekin dC, eds. TNM Classification of Malignant Tumors. 5th ed. New York: John Wiley & Sons, Inc.; 1997.
13. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
14. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol. 2005;23:175-183.
15. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618-1626.
16. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23:2926-2936.
17. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852-3859.
18. Hotta K, Matsuo K. Long-standing debate on cisplatin-versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2007;2:96.
19. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a1 Southwest Oncology Group study. J Clin Oncol. 1998;16:2459-2465.
20. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122-130.
21. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
22. Fossella FV, DeVore R, Kerr RN, et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-2362.
23. Voogd AC, van Gestel K, Ernst MF. Trends in survival of patients with metastatic breast cancer. [comment]. J Clin Oncol. 2005;23:2116.
24. Goulart BH, Martins RG, Lynch TJ. Twenty-two years of Phase III trials for patients with advanced non-small-cell lung cancer: sobering results, [comment]. J Clin Oncol. 2001;19:4089.
25. Smith TJ, Khatcheressian J, Lyman GH, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205.
26. Van Poznak C. Hypercalcemia of malignancy remains a clinically relevant problem. Cancer J. 2006;12:21-23.